Clinical Trials Logo

Gastroesophageal Reflux clinical trials

View clinical trials related to Gastroesophageal Reflux.

Filter by:

NCT ID: NCT01089959 Recruiting - Clinical trials for Gastroesophageal Reflux Disease

Effect of Esomeprazole 40 mg.Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With GERD

ISS
Start date: March 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine if esomeprazole 40 mg. once daily improves not only nighttime symptoms but also significantly reduces conscious awakenings associated with gastroesophageal reflux and consequently improves sleep quality.

NCT ID: NCT01079884 Completed - GERD Clinical Trials

Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance

Start date: July 2008
Phase: N/A
Study type: Interventional

The implications of sleep as it relates to the physiology and pathogenesis of a number of diseases has until recently been ignored. With the evolution of sleep laboratories, there is an emerging recognition of the relationship between sleep and various gastrointestinal diseases- in particular gastroesophageal reflux disease (GERD).( 1-5) It seems intuitive that waking/daytime activities or events may affect sleep and that any consequent sleep dysfunction may reciprocally further affect daytime function

NCT ID: NCT01078064 Terminated - Clinical trials for Gastroesophageal Reflux Disease

Gastric Accommodation and Gastroesophageal Reflux

Start date: March 2010
Phase:
Study type: Observational

Gastroesophageal reflux events generally happen during relaxation of lower esophageal sphincter. This relaxation is a reflex that is triggered by gastric stimuli. The investigators hypothesize that abnormal relaxation of the gastric wall after a meal may lead to reflux events. To test this hypothesis, a study was designed to measure the gastric accommodation in patients undergoing esophageal impedance monitoring.

NCT ID: NCT01065649 Completed - Clinical trials for Gastroesophageal Reflux Disease

Effect of Nortriptyline in Cortical Representation of Heartburn in Nonerosive Reflux Disease (NERD) Patients

NORGERD
Start date: January 2010
Phase: Phase 3
Study type: Interventional

Patients with nonerosive reflux disease (NERD) are less responsive to standard treatment with proton pump inhibitors. The hypothesis of this study was that nortriptyline in analgesic doses may decrease heartburn perception and its corresponding cortical activity measured by magnetic resonance image. Therefore, the aim of this study was to assess the cortical representation of heartburn in patients with NERD under treatment with nortriptyline and placebo.

NCT ID: NCT01059383 Completed - Clinical trials for Gastroesophageal Reflux

Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms

Start date: December 2009
Phase: Phase 2
Study type: Interventional

The study is designed to assess the effect and safety of oral administration of VECAM 40/300 administered at bedtime compared to Esomeprazole 20 mg administered 30-60 minutes before dinner, for control of nighttime and daytime HB and other 24 hour GERD symptoms. The rational for the study is based on the contention that VECAM exhibits potent inhibition of acid secretion and because of its mechanism of action, it can be administered at bedtime without food. Such timing of drug dosing will allow effective inhibition of nighttime acid secretion. Because of its mechanism of action, VECAM exhibits improved 24-hour inhibition of acid secretion and hence, its bedtime administration will not compromise its effect during the daytime. This improved control of acid secretion will predictably result in better control of nighttime as well as daytime heartburn (HB) symptoms.

NCT ID: NCT01058564 Completed - Clinical trials for Gastroesophageal Reflux Disease

A Prospective Evaluation of the Torax Medical Inc. Magnetic Esophageal Sphincter

Start date: May 2008
Phase: Phase 1/Phase 2
Study type: Interventional

Evaluate a novel method of augmenting a weak Lower Esophageal Sphincter (LES).

NCT ID: NCT01058070 Completed - Clinical trials for Gastroesophageal Reflux Disease

An Observational Clinical Feasibility Study of the Magnetic Esophageal Sphincter

Start date: February 2007
Phase: N/A
Study type: Interventional

Magnetic Esophageal Sphincter implant is intended to reinforce Esophageal Sphincter function in the treatment of Gastroesophageal Reflux Disease (GERD)

NCT ID: NCT01057992 Completed - Clinical trials for Gastroesophageal Reflux Disease

A Prospective Evaluation of the Torax Medical Inc. Magnetic Esophageal Sphincter

Start date: March 2007
Phase: Phase 1/Phase 2
Study type: Interventional

A medical device to augment weak lower esophageal sphincter function.

NCT ID: NCT01053585 Completed - Clinical trials for Gastroesophageal Reflux Disease

Structure and Function of the Gastro-esophageal Junction

Start date: February 2007
Phase: N/A
Study type: Interventional

Aims of research project: To identify key features of the gastro-esophageal junction (structure and function) that protects the esophagus from gastro-esophageal reflux investigated by combined high resolution manometry and magnetic resonance imaging. Hypothesis: 1. Functional factors including GEJ function (e.g. sphincter pressure) and proximal gastric distension determine whether or not TLESR occurs; however 2. Structural factors including separation of GEJ anatomy, intra-gastric distribution of the meal and secretions determine whether TLESR is accompanied by no reflux event, gas reflux (belching) or reflux of ingested food and gastric secretion ('true reflux'). 3. Initial findings by descriptive studies in healthy volunteers (study #1) and patients with mild to moderate gastro-esophageal reflux disease (study #2) will be further interrogated by a randomized, double-blind control trial of baclofen in patients with GORD; a medication that inhibits reflux by effects on GOJ function (study #3) .

NCT ID: NCT01053286 Completed - Dysphagia Clinical Trials

Stimulation of Sensation and Improvement in Swallowing Using Oral Capsaicin

Start date: October 2009
Phase: N/A
Study type: Observational

This is a research study to learn more about whether capsaicin, a natural ingredient of chili peppers that makes them taste "hot", can improve swallowing function. The purpose of this study is to evaluate whether sucking on a capsaicin lozenge improves sensation in the throat enough to improve swallowing function.